Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 48,270,472
  • Shares Outstanding, K 107,132
  • Annual Sales, $ 8,497 M
  • Annual Income, $ 3,513 M
  • 60-Month Beta 0.17
  • Price/Sales 5.71
  • Price/Cash Flow 13.57
  • Price/Book 4.40
Trade REGN with:

Options Overview

Details
  • Implied Volatility 37.85%
  • Historical Volatility 16.22%
  • IV Percentile 37%
  • IV Rank 9.77%
  • IV High 119.58% on 03/16/20
  • IV Low 29.00% on 02/12/21
  • Put/Call Vol Ratio 0.83
  • Today's Volume 3,857
  • Volume Avg (30-Day) 4,847
  • Put/Call OI Ratio 0.72
  • Today's Open Interest 37,229
  • Open Int (30-Day) 34,165

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate 8.02
  • Number of Estimates 1
  • High Estimate 8.02
  • Low Estimate 8.02
  • Prior Year 5.87
  • Growth Rate Est. (year over year) +36.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
445.57 +1.12%
on 02/26/21
541.97 -16.86%
on 01/27/21
-93.53 (-17.19%)
since 01/26/21
3-Month
445.57 +1.12%
on 02/26/21
558.91 -19.38%
on 01/26/21
-57.74 (-11.36%)
since 11/25/20
52-Week
418.01 +7.79%
on 03/13/20
664.64 -32.21%
on 07/20/20
-7.35 (-1.61%)
since 02/26/20

Most Recent Stories

More News
Regeneron Announces Positive Phase 2 Data Evaluating Fel d 1 Antibody Cocktail in Cat-allergic Patients with Mild Asthma

, /PRNewswire/ --

REGN : 450.57 (-0.58%)
EMA Issues Advice on Regeneron's Antibody Cocktail (casirivimab with imdevimab) for Certain COVID-19 Patients

, /PRNewswire/ --

REGN : 450.57 (-0.58%)
Intravitreal (IVT) Injectables Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027

The Global is poised to register a CAGR of over 4.7% during the forecast period 2020 to 2027.

ALIM : 8.07 (+1.51%)
AGN : 193.02 (+0.02%)
NVS : 85.91 (-0.92%)
REGN : 450.57 (-0.58%)
VRX.TO : 30.80 (-3.33%)
Independent Data Monitoring Committee Finds Clear Efficacy for REGEN-COV™ (casirivimab with imdevimab) in Phase 3 COVID-19 Outpatient Outcomes Trial

, /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: ) today announced changes to the Phase 3 trial assessing investigational REGEN-COV™ (casirivimab with imdevimab) in non-hospitalized patients...

REGN : 450.57 (-0.58%)
The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Incyte, Nektar Therapeutics, Immunome and Otonomy

The Zacks Analyst Blog Highlights: Regeneron Pharmaceuticals, Incyte, Nektar Therapeutics, Immunome and Otonomy

REGN : 450.57 (-0.58%)
INCY : 78.66 (+0.27%)
NKTR : 22.69 (+1.11%)
OTIC : 2.91 (-1.19%)
IMNM : 39.58 (+3.50%)
Biotech Stock Roundup: Regulatory Updates From REGN, INCY, & Other Updates

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Incyte (INCY) and Nektar (NKTR).

REGN : 450.57 (-0.58%)
SNY : 45.89 (+0.20%)
MRK : 72.62 (-2.68%)
INCY : 78.66 (+0.27%)
NKTR : 22.69 (+1.11%)
OTIC : 2.91 (-1.19%)
IMNM : 39.58 (+3.50%)
Promising Oncology Breakthroughs Sparking Wave of Next Generation of Brain Cancer Therapies

, /PRNewswire/ --   -  The way we think about treating brain cancers is being quietly revolutionized, buried beneath recent headline-grabbing announcements pertaining to COVID-19. A series of discoveries...

ONCY : 3.21 (-7.49%)
ONC.TO : 4.09 (-6.19%)
INO : 11.10 (-3.39%)
REGN : 450.57 (-0.58%)
SNY : 45.89 (+0.20%)
NWBO : 1.4500 (+2.11%)
Promising Oncology Breakthroughs Sparking Wave of Next Generation of Brain Cancer Therapies

The way we think about treating brain cancers is being quietly revolutionized, buried beneath recent ...

ONCY : 3.21 (-7.49%)
INO : 11.10 (-3.39%)
REGN : 450.57 (-0.58%)
SNY : 45.89 (+0.20%)
NWBO : 1.4500 (+2.11%)
ONC.TO : 4.09 (-6.19%)
FDA Issues New Guidelines for COVID-19 Vaccines, Tests, Drugs

The FDA encourages companies to evaluate the impact of COVID-19 virus variants on the efficacy or performance of their COVID-19 vaccines, tests and medicines.

JNJ : 158.46 (-2.64%)
REGN : 450.57 (-0.58%)
PFE : 33.49 (-0.98%)
MRNA : 154.81 (+4.33%)
LLY : 204.89 (+0.52%)
BNTX : 109.03 (-2.94%)
FDA Approves Libtayo® (cemiplimab-rwlc) Monotherapy for Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%

and , /PRNewswire/ -- 

REGN : 450.57 (-0.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic medicines for the treatment of serious medical conditions. Regeneron has therapeutic candidates for the potential treatment of obesity, rheumatoid arthritis, cancer, and asthma...

See More

Key Turning Points

3rd Resistance Point 468.24
2nd Resistance Point 462.71
1st Resistance Point 456.64
Last Price 450.57
1st Support Level 445.03
2nd Support Level 439.50
3rd Support Level 433.43

See More

52-Week High 664.64
Fibonacci 61.8% 570.43
Fibonacci 50% 541.33
Fibonacci 38.2% 512.22
Last Price 450.57
52-Week Low 418.01

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar